Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
Elite Pharmaceuticals (OTCQB:ELTP) announced that it will release its financial results for the second quarter of the 2023 fiscal year, ending September 30, 2022, on November 14, 2022. A live conference call is scheduled for November 15, 2022, at 11:30 AM EST, where management will discuss the financial and operational outcomes as well as provide a business update. Investors can submit questions via email prior to the call. Elite focuses on developing and manufacturing niche generic products, with a registered facility in Northvale, NJ.
- Scheduled release of financial results may indicate a commitment to transparency and investor communication.
- Potential for growth as Elite develops and licenses multiple generic products, enhancing market position.
- None.
Financials for Second Quarter Fiscal Year 2023 Ended September 30, 2022 will be released on November 14, 2022
NORTHVALE, NJ / ACCESSWIRE / November 8, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2023 fiscal year will be released on Monday, November 14, 2022. Elite's management will host a live conference call Tuesday, November 15th at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
| Date: | November 15, 2022 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EST on Friday, November 11, 2022 Financial questions by 7:00 PM EST on Monday, November 14, 2022 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
SOURCE: Elite Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/723965/Elite-Pharmaceuticals-Inc-to-Host-Conference-Call-to-Provide-Corporate-Update-and-Discuss-Second-Quarter-2023-Financial-Results-on-November-15-2022
FAQ
What date will Elite Pharmaceuticals release their Q2 financial results for FY 2023?
When is the conference call to discuss Elite Pharmaceuticals' financial results?
How can investors submit questions for the conference call?
What is the purpose of the upcoming conference call by Elite Pharmaceuticals?
Where can I find the audio replay of Elite Pharmaceuticals' conference call?
